Search Everything

Find articles, journals, projects, researchers, and more

Back to Articles

Economics and industry do not mean ethical conduct in clinical trials

Authors:
Joel Lexchin

Abstract

Clinical trials present an ethical dilemma for pharmaceutical companies. While companies may want to undertake and report these trials in an ethical manner, negative results can significantly affect product sales. There is accumulating evidence that company-financed trials are biased in favor of the product that the company makes. Ethical conduct in this article is defined as whether the trials are conducted in the best interests of the participants and/or reported in the best interests of patients. Nine examples of how clinical trials are violating multiple articles in the Declaration of Helsinki are discussed using concrete case reports from the literature. The recognition of ethical problems in company run trials is not something new, but to date no meaningful action has been taken to resolve this issue. What is necessary is to separate the financing of clinical trials from their conduct.

Keywords: Clinical trials Developing countries Ethics Ghost writing Pharmaceutical industry Seeding trials Withholding data
DOI: https://doi.ms/10.00420/ms/5077/SJIWE/BZD | Volume: 6 | Issue: 1 | Views: 0
Download Full Text (Free)
Article Document
1 / 1
100%

Subscription Required

Your subscription has expired. Please renew your subscription to continue downloading articles and access all premium features.

  • Unlimited article downloads
  • Access to premium content
  • Priority support
  • No ads or interruptions

Upload

To download this article, you can either subscribe for unlimited downloads, or upload 0 items (articles and/or projects) to download this specific article.

Total: 0 / 0
  • Choose any combination (e.g., 2 articles + 1 project = 3 total)
  • After uploading, you can download this specific article
  • Or subscribe for unlimited downloads of all articles